1)Sasako M, Sakuramoto S, Katai H, et al:Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer. J Clin Oncol 29:4387-4393, 2011.
2)Tsuburaya A, Mizusawa J, Tanaka Y, et al:Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Cancer 101:653-660, 2014.
3)Iwasaki Y, Terashima M, Mizusawa J, et al:Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer(JCOG0501):an open-label, phase 3, randomized controlled trial. Gastric Cancer 24:492-502, 2021.
4)Al-Batran SE, Homann N, Goetze PC, et al:Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma(FLOT4):a randomized phase 2/3 trial. Lancet 393:1948-1957, 2019.
5)Fukagawa T, Katai H, Mizusawa J, et al:A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage Ⅲ gastric cancer(JCOG1301A). Gastric Cancer 21:68-73, 2018.
6)Adam R, Chiche L, Aloia T, et al:Hepatic resection for noncolorectal nonendocrine liver metastases. Ann Surg 244:524-535, 2006.
7)Kroese TE, van Laarhoven HWM, Schoppman SF, et al:Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer:a Delphi consensus study in Europe. Eur J Cancer 185:28-39, 2023.
8)日本胃癌学会(編);胃癌治療ガイドライン,医師用2021年7月改訂,第6版.金原出版,2021
9)Yoshida K, Yamaguchi K, Okumura N, et al:Is conversion therapy possible in stage Ⅳ gastric cancer:the proposal of new biological categories of classification. Gastric Cancer 19:329-338, 2016.
10)Yoshida K, Yasufuku I, Terashima M, et al:International retrospective cohort study of conversion therapy for Stage Ⅳ gastric cancer. Ann Gastroenterol Surg 6:227-240, 2021.